A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Investigational Site Number : 1580002, Tainan City

Investigational Site Number : 0360001, Melbourne

Investigational Site Number : 0560001, Leuven

Investigational Site Number : 0360002, Heidelberg West

Investigational Site Number : 2500002, Marseille

Investigational Site Number : 2330001, Tallinn

Investigational Site Number : 3800003, Rozzano

Investigational Site Number : 3800001, Milan

Investigational Site Number : 3800002, Milan

Duke University Medical Center Site Number : 8400008, Durham

Investigational Site Number : 7240003, Madrid / Madrid

Investigational Site Number : 7240004, Madrid / Madrid

Investigational Site Number : 2760003, Hanover

Investigational Site Number : 7240005, Pamplona

Tennessee Oncology, PLLC Site Number : 8400006, Nashville

Investigational Site Number : 2500003, Nantes

Investigational Site Number : 2500005, Nantes

Investigational Site Number : 2760001, Essen

The University of Kansas Clinical Research Center Site Number : 8400004, Fairway

Mary Crowley Cancer Research Center Site Number : 8400003, Dallas

Investigational Site Number : 2500001, Villejuif

Massachusetts General Hospital Site Number : 8400001, Boston

Dana Farber Cancer Institute Site Number : 8400101, Boston

Investigational Site Number : 1240003, Calgary

Investigational Site Number : 1240001, Toronto

Investigational Site Number : 1240002, Montreal

Investigational Site Number : 5280001, Rotterdam

Investigational Site Number : 5280002, Utrecht

Investigational Site Number : 4100001, Seoul

Investigational Site Number : 4100002, Seoul

Investigational Site Number : 7240002, Barcelona

Investigational Site Number : 7240001, Barcelona

Investigational Site Number : 8260001, Glasgow

Investigational Site Number : 8260002, Cardiff